Infusion Express Taps Amendola Communications to Support Growth Trajectory
SCOTTSDALE Ariz. Dec. 14 2016 PRNewswire Amendola Communications an awardwinning healthcare marketing and public relations agency has announced it has been chosen as the agency of record by Infusion...
View ArticleRedHill's Phase III study of RHB104 in Crohn's disease to continue as planned
RedHill Biopharma has received a unanimous recommendation from the independent Data and Safety Monitoring Board DSMB to continue the MAP US phase III study with RHB104 for Crohns disease as planned...
View ArticleRedHill Biopharma and IntelGenx Announce Definitive Agreement for...
RedHill and its codevelopment partner IntelGenx Corp. IntelGenx have signed a definitive agreement with Pharmatronic Co. granting an exclusive license to commercialize the acute migraine drug...
View ArticleGalapagos Release The Lancet Publishes FITZROY Study Results With Filgotinib...
Life Sciences Jobs ...
View ArticleComment Filgotinib for Crohn's diseaseexpanding treatment options
For decades since the disease's first description in 1932 there have been few effective options available to treat Crohn's disease other than corticosteroids aminosalicylates thiopurines and...
View ArticleArticles Clinical remission in patients with moderatetosevere Crohn's disease...
Filgotinib induced clinical remission in significantly more patients with active Crohn's disease compared with placebo and had an acceptable safety profile.
View ArticleTiGenix raises $35.65 million gross proceeds with NASDAQ IPO
PRESS RELEASEREGULATED INFORMATION TiGenix raises $35.65 million gross proceeds with NASDAQ IPO Leuven BELGIUM DecemberÂ15 2016 300h CET TiGenix NV Euronext Brussels TIG; "TiGenix" an...
View ArticleBRIEFGalapagos reports publication of Phase 2 study with filgotinib in...
"FITZROY was the first doubleblind placebocontrolled study to use centrally readendoscopies to ensure the selective recruitment of patients with active disease includingmucosal ulceration" Dr Vermeire
View ArticleTiGenix Raises $35.65M Gross in NASDAQ IPO
TiGenix a Leuven Belgiumbased biopharmaceutical company focused on developing therapeutics from its platforms of allogeneic expanded stem cells has nearly completed its secondround NASDAQ IPO with...
View ArticleThe Lancet publishes FITZROY study results with filgotinib in Crohn's disease
  Mechelen Belgium; 12 December 2016 Galapagos NV Euronext & NASDAQ GLPG reports publication of the Phase 2 study with filgotinib in Crohn's disease in The Lancet....
View ArticleJanssen Submits Application Seeking FDA Approval of STELARAÂ Ustekinumab for...
HORSHAM Pa. Dec. 16 2016 PRNewswire Janssen Biotech Inc. Janssen announced today the submission of a Supplemental Biologics License Application sBLA to the U.S. Food and Drug Administration FDA seeking...
View ArticleSoligenix Announces Closing of Public Offering
PRINCETON N.J. Dec. 16 2016 PRNewswire Soligenix Inc. Nasdaq SNGX a latestage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
View ArticleEisai and Arena Pharmaceuticals Announce Regulatory Approval of BELVIQÂ...
WOODCLIFF LAKE N.J. and SAN DIEGO Dec. 19 2016 PRNewswire Eisai Inc. and Arena Pharmaceuticals Inc. NASDAQ ARNA today announced that Eisai Laboratrios Ltda. a subsidiary of Eisai Inc. has received...
View ArticleRedHill Biopharma Announces First Patient Dosed in Phase IbII Study with...
The first patients have been screened and a first patient has been dosed in the openlabel dose escalation Phase IbII study with YELIVAÂÂABC294640 for multiple myeloma The Phase IbII clinical study is...
View ArticleTiGenix announces closing of NASDAQ IPO
PRESS RELEASE TiGenix announces closing of NASDAQ IPO Leuven BELGIUM DecemberÂ20 2016 1600h CET TiGenix NV Euronext Brussels & NASDAQ TIG; "TiGenix" an advanced...
View ArticleTakeda makes 10 million equity investment in TiGenix
PRESS RELEASE REGULATED INFORMATION INSIDE INFORMATION Takeda makes 10 million equity investment in TiGenix Leuven BELGIUM DecemberÂ20 2016 2201h CET TiGenix NV Euronext Brussels and NASDAQ TIG;...
View ArticleRedHill Biopharma Announces Proposed Concurrent Public Offering and...
TELAVIV Israel Dec. 20 2016 GLOBE NEWSWIRE RedHill Biopharma Ltd. NASDAQRDHL TASERDHL "RedHill" or the "Company" a biopharmaceutical company primarily focused on the...
View ArticleFeinstein Institute Scientists Discover More Detail About the Vagus Nerve and...
MANHASSET N.Y. Dec. 21 2016 PRNewswireUSNewswire Researchers at The Feinstein Institute for Medical Research discovered more details about how the vagus nerve interacts with the immune system better...
View ArticleBiology A slowmotion epidemic
The symptoms of Crohn's disease and ulcerative colitis the two main forms of inflammatory bowel disease IBD can be severe and lifelong. And the condition is becoming increasingly common worldwide.
View Article